liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Adding nanotechnology to the metastasis treatment arsenal
Columbia University Medical Center, USA.
University of Oslo, Norway.
University of Cambridge, UK.
Linköping University, Department of Clinical and Experimental Medicine, Division of Cell Biology. Linköping University, Faculty of Medicine and Health Sciences.
Show others and affiliations
2019 (English)In: TIPS - Trends in Pharmacological Sciences, ISSN 0165-6147, E-ISSN 1873-3735, Vol. 40, no 6, p. 403-418Article, review/survey (Refereed) Published
Abstract [en]

Metastasis is a major cause of cancer-related mortality, accounting for 90% of cancer deaths. The explosive growth of cancer biology research has revealed new mechanistic network information and pathways that promote metastasis. Consequently, a large number of antitumor agents have been developed and tested for their antimetastatic efficacy. Despite their exciting cytotoxic effects on tumor cells in vitro and antitumor activities in preclinical studies in vivo, only a few have shown potent antimetastatic activities in clinical trials. In this review, we provide a brief overview of current antimetastatic strategies that show clinical efficacy and review nanotechnology-based approaches that are currently being incorporated into these therapies to mitigate challenges associated with treating cancer metastasis.

Place, publisher, year, edition, pages
Cambridge, Massachusets: Elsevier, 2019. Vol. 40, no 6, p. 403-418
Keywords [en]
metastasis; nanotechnology; chemotherapy; combination therapy
National Category
Other Clinical Medicine Cancer and Oncology Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:liu:diva-156845DOI: 10.1016/j.tips.2019.04.002ISI: 000469437500007PubMedID: 31076247OAI: oai:DiVA.org:liu-156845DiVA, id: diva2:1315714
Note

Funding agencies: EU H2020 Marie Sklodowska-Curie Individual Fellowship [706694]; Wolfson College (University of Cambridge, UK); MIIC Seed Grant from Linkoping University (LiU), Sweden

Available from: 2019-05-14 Created: 2019-05-14 Last updated: 2019-09-24

Open Access in DiVA

fulltext(2497 kB)422 downloads
File information
File name FULLTEXT01.pdfFile size 2497 kBChecksum SHA-512
98ae268b94f549905b7e200dce577fb9f7cc0adc29daae098f5916711eecb6be4282bac1509102638b2e14ff299c2c8694593172cf1cbd11226eb0d2d38cd995
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Wiechec, EmiliaPatra, Hirak

Search in DiVA

By author/editor
Wiechec, EmiliaPatra, Hirak
By organisation
Division of Cell BiologyFaculty of Medicine and Health Sciences
In the same journal
TIPS - Trends in Pharmacological Sciences
Other Clinical MedicineCancer and OncologyPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 434 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 359 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf